We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




CT Scans Predict Chemotherapy Response in Pancreatic Cancer Patients

By MedImaging International staff writers
Posted on 24 Mar 2014
Print article
Computed tomography (CT) scans routinely taken to guide the treatment of pancreatic cancer may also provide an important secondary benefit. According to new research, the scans also show how well chemotherapy will penetrate a tumor, predicting the effectiveness of treatment.

The research, published March 10, 2014, in the Journal of Clinical Investigation, is the first human study to address the issue of chemotherapy delivery to pancreatic tumors, a problem previously shown in animal studies. “We found that the distribution of intravenous dye used in CT scans is a surrogate for chemotherapy delivery in the tumor,” said Jason Fleming, MD, a professor of surgical oncology at the University of Texas MD Anderson Cancer Center (Houston, TX, USA), and corresponding author of the study. “Our results indicate that combining data from routine CT scans and using a mathematical formula developed by our team can predict response, guide patient treatment and lead to efforts to improve drug delivery.”

Pancreatic tumors contain disorganized or nonfunctional blood vessels, high proportions of fibrotic tissue and molecular variations that create barriers for a drug to reach its target. It's a disease with a poor prognosis and the American Cancer Society estimates more than 39,000 people will die in 2014 as a result.

“Chemotherapy is used every day, however we’ve done very little to demonstrate that the drug actually reaches the tumor efficiently,” Prof. Fleming said. “Results from our previous clinical trials at MD Anderson taught us that when chemotherapy kills most of a patient’s tumor, the patient has a better chance of being a long-term survivor.”

Researchers first enrolled 12 patients with primary pancreatic disease who would undergo a surgical resection. During surgery, each patient received an infusion of the chemotherapy drug gemcitabine. After surgery, the tumor DNA was analyzed for penetration of gemcitabine. Gemcitabine is delivered to tumor DNA primarily through a protein called the human equilibrative nucleoside transporter (hENT1). Previous studies have shown its expression varies in pancreatic tumors, linking the protein to drug response.

For patients in the study with dense, fibrotic tumors and not much hENT1 protein, the chemotherapy was delivered constantly but its uptake was minimal since the drug was not reaching cancer cells, according to Prof. Fleming. The researchers discovered that gemcitabine penetrated tumors at varying levels in the group of 12 patients and those with greater gemcitabine levels responded better to therapy and had improved outcomes. After seeing this disparity, the team examined past CT scans from another group of patients to compare how the drug reached tumor cells.

The researchers analyzed scans from 176 patients (12 who received gemcitabine infusion during surgery, 110 who received presurgical gemcitabine-based chemoradiation and 55 who received upfront surgery to remove the tumor). After reviewing the data, researchers noticed visual differences in tumors as a result of the CT contrast being absorbed differently. Based on these observations, Prof. Fleming and his colleagues began to question whether the intravenous contrast used for CT scans predicted the path and absorption of gemcitabine. It appeared that this hypothesis was correct.

By using models to measure factors that influence drug delivery, the researchers found resected tumors revealed up to six-fold differences in gemcitabine incorporation. “This work is showing that solid tumors are much more heterogeneous than we thought with respect to drug delivery,” Dr. Fleming said. “Going forward the implication is that molecular information from a biopsy of the tumor can be combined with data from a standard CT scan to place patients into categories that predict their response to therapy.”

Furthermore, Prof. Fleming noted that the trial implications are broad and could apply to other solid tumors. Researchers are beginning to look at existing drugs, such as losartan, a drug for high blood-pressure, as it could change the makeup of dense tumors, allowing better delivery of chemotherapy for patients who otherwise would have a poor response. “The nice thing is that we can measure the effect of these new and repurposed drugs by using intravenous contrast in CT scans as a surrogate, so we don’t have to commit a patient to receive a cancer drug until we know it improves the tumor characteristics,” he added.

Future research is needed, according to the investigators, to standardize this approach of matching patients’ tumors to the most effective drugs.

Related Links:

University of Texas MD Anderson Cancer Center

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound System
Acclarix AX9
Mammography System
MAMMOVISTA B.smart
New
Oncology Information System
RayCare

Print article

Channels

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The Cinematic Reality app enables interaction with realistic renderings of human anatomy (Photo courtesy of Siemens)

AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning

Siemens Healthineers (Erlangen, Germany) has launched an app designed for Apple Vision Pro that allows users including surgeons, medical students, or patients to view immersive, interactive holograms of... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.